The pharmaceutical industry is often considered a safe haven for investors, due to the steady demand for healthcare-related services. However, the recent spike in popularity for blockbuster weight-loss drugs clearly shows that there’s still plenty of room for explosive growth in drug stocks, too – and not just under-the-radar biotechs, either. Here, we’ll take a look at two mega-cap pharmaceutical stocks that could continue to expand on robust global demand for a new generation of anti-obesity treatments. Read on to find out what Wall Street expects next in 2024 for these drug stock standouts….